2024
Evaluation of SARS-CoV-2 anti-Spike antibody levels and breakthrough infection risk among vaccinated adults in North Lebanon
Nour D, Ismail M, Osman M, Rafei R, Kasir D, Dabboussi F, Colson P, Hamze M. Evaluation of SARS-CoV-2 anti-Spike antibody levels and breakthrough infection risk among vaccinated adults in North Lebanon. PLOS ONE 2024, 19: e0302579. PMID: 38722969, PMCID: PMC11081361, DOI: 10.1371/journal.pone.0302579.Peer-Reviewed Original ResearchConceptsImmune responseAntibody titersAntibody levelsAnti-spike antibody levelsCharacteristics of immune responsesWaning immune responsesMultivariate logistic regression modelSARS-CoV-2 antibody titersLevel of antibody titerVaccinated patientsBNT162b2 vaccineUnivariate analysisLogistic regression modelsSputnik V vaccineBlood specimensPfizer-BioNTechVaccine doseImmune statusVaccinated adultsSARS-CoV-2InfectionNorth LebanonVaccineAstraZeneca vaccineTiters
2023
Booster vaccination protection against SARS-CoV-2 infections in young adults during an Omicron BA.1-predominant period: A retrospective cohort study
Wan J, Cazer C, Clarkberg M, Henderson S, Lee S, Meredith G, Osman M, Shmoys D, Frazier P. Booster vaccination protection against SARS-CoV-2 infections in young adults during an Omicron BA.1-predominant period: A retrospective cohort study. PLOS Medicine 2023, 20: e1004153. PMID: 36626376, PMCID: PMC9876273, DOI: 10.1371/journal.pmed.1004153.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionInitial vaccination seriesPositive SARS-CoV-2 PCR testSARS-CoV-2 PCR testVaccination seriesBooster doseBooster vaccinationCohort studyStudy periodYoung adultsAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSyndrome coronavirus 2 infectionSevere coronavirus disease 2019Polymerase chain reaction testingCoronavirus 2 infectionRetrospective cohort studyPCR testMultivariable Poisson regressionSARS-CoV-2 variantsStatistical analysis planCoronavirus disease 2019Active surveillance approachSARS-CoV-2World Health Organization
2022
The impact of vaccination on the burden of invasive pneumococcal disease from a nationwide surveillance program in Lebanon: an unexpected increase in mortality driven by non-vaccine serotypes
Reslan L, Youssef N, Boutros C, Assaf-Casals A, Fayad D, Khafaja S, Akl F, Finianos M, Rizk A, Shaker R, Zaghlout A, Lteif M, Hafi B, Moumneh M, Feghali R, Ghanem S, Jisr T, Karayakoupoglou G, Naboulsi M, Hamze M, Samad S, Khoury E, Sarraf R, Osman M, Raad E, Amin H, Abadi I, Abdo H, Chedid M, Chamseddine F, Barakat A, Houmani M, Haddad A, Nour G, Mokhbat J, Daoud Z, El-Zaatari M, Sokhn E, Ghosn N, Ammar W, Hamadeh R, Matar G, Araj G, Dbaibo G. The impact of vaccination on the burden of invasive pneumococcal disease from a nationwide surveillance program in Lebanon: an unexpected increase in mortality driven by non-vaccine serotypes. Expert Review Of Vaccines 2022, 21: 1905-1921. PMID: 36342411, DOI: 10.1080/14760584.2022.2143349.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseNon-vaccine typesPneumococcal conjugate vaccinePCV13 eraPneumococcal diseaseBurden of IPDSurveillance programHigher valency vaccinesPost-PCV7 eraRecommendation of vaccinationNon-vaccine serotypesImpact of vaccinationNationwide surveillance programAntimicrobial resistance profilesPCV7 eraPCV7 serotypesConjugate vaccineSerotype distributionUnvaccinated populationAntimicrobial stewardshipMortality rateAge groupsResistance profilesStudy periodSignificant decrease